New Leukaemia Drug Kills 90pc of Cancer in First Dose

by Bidita Debnath on  October 27, 2014 at 10:36 PM Research News
RSS Email Print This Page Comment bookmark
Font : A-A+

New leukaemia drug has given hope to patients as it kills nearly 90 per cent of their cancer in the first dose.

Gazyva, which so powerful it can send patients into shock, comes with a whopping 42,000 dollar bill, News.com.au reported.
 New Leukaemia Drug Kills 90pc of Cancer in First Dose
New Leukaemia Drug Kills 90pc of Cancer in First Dose

Though the drug has been approved for use in Australia but not yet subsidised by the Pharmaceutical Benefits Scheme and has some serious side effects including increased risk of infections, including lower white blood cell counts and reduce the ability of the blood to clot, fever, cough, and muscle and joint pain.

A study published in the New England Journal of Medicine earlier this year showed Gazyva delayed the progression of the cancer in patients using the drug in combination with an older chemotherapy by 26.7 months, 15 months longer than progression free survival in patients using standard treatment.

Source: ANI

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

More News on:

Drug Toxicity Cancer and Homeopathy Signature Drug Toxicity Cancer Facts Cancer Tattoos A Body Art Common Lifestyle Habits that Cause Diseases Health Benefits of Dandelion Plant 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor
Advertisement

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook

News Category

News Archive